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Background: Pelvic inflammatory disease (PID) is the result of infection ascending through the endocervix to the
uterus and fallopian tubes. Inflammation driven by infected host cells appears to be central to the development of
tissue damage and associated reproductive complications. Nonsteroidal anti-inflammatory agents (NSAIDs) therefore
have the potential to reduce the sequelae associated with pelvic infection.
Methods: A search of four electronic reference databases, an internet search for relevant grey literature and a
review of the bibliographies of identified publications was used to identify studies evaluating NSAIDs in the
management of PID. A predefined search strategy was used to identify studies that included women with PID aged
over 16 and diagnosed after 1980. Randomized controlled trials, nonrandomized controlled trials, and cohort
studies with comparison group data were included without language restriction. Two reviewers independently
assessed the studies against agreed criteria and extracted relevant data using a standardized pro forma. A
meta-analysis to calculate the relative risk associated with NSAID use was planned if appropriate.
Results: Forty-three studies were identified. After reviewing abstracts or full texts, two randomized controlled trials
were found to meet the selection criteria for inclusion. The use of NSAIDs was reported to improve tubal patency,
reduce pelvic adhesions and reduce suprapubic pain but the studies were of poor quality with a high risk of bias.
Meta-analysis of the data was not performed.
Conclusions: Insufficient data is available to support or refute the efficacy of NSAIDs in the prevention of short or
long-term complications of PID.
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Pelvic inflammatory disease (PID) is an infectious and
inflammatory disorder of the uterus, fallopian tubes and
adjacent pelvic structures as a result of ascending infec-
tion from the endocervix. The highest prevalence is in
16- to 24-year-olds, reflecting the high rate of bacterial
sexually transmitted infections found in this age group [1].
Complications include infertility, ectopic pregnancy and
chronic pelvic pain, and can result in considerable physical
and emotional morbidity, in addition to a significant fi-
nancial burden on healthcare services.* Correspondence: divya.dhasmana@nhs.net
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article, unless otherwise stated.Chlamydia trachomatis and Neisseria gonorrhoeae are
the causative agents in approximately 40% of cases of PID
[2].Mycoplasma genitalium,Trichomonas vaginalis, Herpes
simplex type 2, bacterial vaginosis-associated microorgan-
isms and anaerobic organisms endogenous to the vaginal
flora have also been isolated from the upper genital tract,
although their role in the reproductive complications of
pelvic infection remains unclear [3-8]. Inflammation
driven by infected host cells appears central to the de-
velopment of reproductive complications. Epithelial cells
are the primary target of chlamydial infection, and are
thought to initiate and sustain the host response through
the secretion of chemokines, which recruit inflammatory
leukocytes to the site of infection, and which also induce
and regulate the inflammatory process. For example, Toll-liketral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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sponse and has a role in both the production of inflamma-
tory mediators and the development of upper genital tract
pathology [9].
The adaptive immune response is also triggered by the
release of inflammatory mediators. The CD4 Th-1 re-
sponse is thought to be the main mechanism of infection
resolution. Reinfection is common and it is proposed that
an amplified Th-1 response to chronic or repeat infection
might promote tissue damage and scarring. Chlamydia
heat shock protein-60 (Chsp60) has been investigated as
the possible cause of a delayed hypersensitivity reaction
leading to a heightened inflammatory response. It has a
highly conserved amino acid sequence, chlamydial and
human sequences being 48% homologous. This similar-
ity may result in an autoimmune response due to cross
reactivity between self-hsp and Chsp-60. However, des-
pite animal data supporting this hypothesis, the PID
Evaluation and Clinical Health (PEACH) study did not
demonstrate a correlation between increased antibody
titres to Chsp60 and PID-related complications [10]. In
contrast, antibodies to Chlamydia trachomatis elemen-
tary bodies, the extracellular form of Chlamydia, were
independently associated with reduced rates of preg-
nancy and elevated rates of recurrent PID at 7 years of
follow-up. It remains unclear whether chlamydial anti-
body titres simply reflect increased exposure, in terms
of either chronicity of infection or reinfection, or if their
presence represents a direct role in pathogenesis.
A number of host factors and cellular responses have
been associated with susceptibility or protection from the
development of reproductive complications. For example,
the production of interferon-γ by peripheral blood mono-
nuclear cells stimulated with Chsp60 has been strongly as-
sociated with protection against new Chlamydia infection
[11]. Host factors that regulate the Th-1 response may also
therefore be important in modifying the risk of long-term
complications.
Current treatment guidelines focus on the eradication
of infection using a regimen of broad-spectrum antibi-
otics [12,13]. The role of surgery is limited to the early
division of adhesions and drainage of pelvic collections.
No treatment is currently recommended to prevent or
reduce the inflammatory process.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a
group of analgesic drugs that act as nonselective inhibitors
of the cyclooxygenase (COX) enzyme. The COX enzyme
is required for the formation of prostaglandins that regu-
late the inflammatory response. There are two forms of
this enzyme: a constitutive form, COX-1, that is present in
the gastric mucosa, and an inducible form, COX-2; the
latter form is preferentially expressed at sites of inflamma-
tion. Inhibition of the former leads to the well-described
gastric side effects of NSAIDs, and inhibition of the latterto its therapeutic anti-inflammatory effects. Both COX-1
and COX-2 are expressed in the uterine epithelium at dif-
ferent times in early pregnancy [14], whilst COX enzymes
are also known to be involved in endometrial pathology
[15]. Animal studies have demonstrated that the immu-
noexpression of COX-2 was found to be strongest in
endometrium with acute endometritis compared with
normal endometrium or chronic endometritis [16]. In
addition, COX-2 expression has been found to be an
independent prognostic factor in uterine leiomyosarco-
mas [17].
The role of the COX enzyme in inflammation and adhe-
sion formation in the murine model is well established
and provides a mechanism for NSAIDs, through COX
inhibition, to affect PID outcomes. Trauma to rat paws
has been shown to induce expression of COX-2 and in
turn increase the production of prostaglandin, resulting
in oedema and a hyperalgesic response [18]. This path-
way was blocked following the selective inhibition of
COX-2 with indomethacin. Furthermore, following the
induction of peritoneal fibrosis in rats, provision of NSAID
was shown to reduce the extent and severity of adhesions
in comparison with intraperitoneal saline or placebo [19].
Nonsteroidal anti-inflammatory drugs, commonly used
as analgesics, may therefore provide a means of reducing
the inflammation and subsequent fibrosis that leads to
tubal damage associated with PID and its complications.
Objectives
The objective of this review was to assess the clinical effect-
iveness of NSAIDs (in addition to antibiotic therapy) in




A search strategy was developed and used to identify
relevant studies (Additional file 1). Databases were
searched between March and May 2011 and again in
June 2014 as follows: MEDLINE from PubMed 1980 to
present, EMBASE 1980 to present, CINAHL 1981 to
present and the Cochrane library. Searches were repeated
in grey literature (Additional file 2) to identify any unpub-
lished and ongoing research. No language restriction was
applied.
Two reviewers independently searched each database,
scanned titles and abstracts, and retrieved papers that ful-
filled the predefined inclusion criteria, described next. In
case of disagreement, a final decision on whether to include
a study was made by consensus with a third reviewer.
Types of study
Randomized controlled trials (RCTs), nonrandomized
controlled trials and cohort studies reporting data from
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and case reports were excluded.
Types of participant
Studies of females 16 years or over diagnosed clinically
with PID as an inpatient or outpatient since 1980 were
included.
Types of intervention
Studies in which NSAIDs were given for the treatment
of PID in combination with antibiotic therapy and where
data were also reported from a comparison group were
eligible for inclusion. The comparators included placebo
or any intervention given in addition to antibiotic ther-
apy for the treatment of PID, including paracetamol or
opiates.
Types of outcome
Short and long-term clinical markers of effectiveness
were included.
Short term outcomes:
 Severity of pain.
 Time to resolution of pain.
 Length of inpatient stay.
Long-term outcomes:
 Chronic pelvic pain.
 Tubal patency.




A standardized data extraction form was designed
and, after internal review by the study team, utilized
(Additional file 3). Two reviewers independently extracted
data from the articles and disagreements were resolved
following discussion. The authors of identified papers
were contacted to request additional information where
required. Study quality was assessed using the Cochrane
Risk-of-Bias Tool [20].
Data synthesis
Articles were stratified by type of NSAID and compara-
tor. Key findings were reported.
Results
Forty-three studies were identified by the search strat-
egy. Thirty-six articles were excluded after title and ab-
stract review, as they did not meet the predefined
inclusion criteria. A further five articles were excluded
after full text or abstract review of English translations(three trials did not include a comparator arm [21-23],
one study compared the efficacy of two different NSAIDs
[24] and one study did not give NSAIDs in addition to
standard antibiotic therapy [25]). The remaining two stud-
ies were included for data extraction. References from
these were reviewed for further relevant studies but none
were identified.
Study design
The two studies included for data extraction were RCTs.
Bassil et al. [26] randomized 40 women with acute salpin-
gitis or PID to receive piroxicam, a nonselective COX
inhibitor, or no NSAID in addition to antibiotic therapy.
Goffi et al. [27] randomized 42 women with mild acute
PID to receive fentiazac, a new NSAID, or placebo in
addition to antibiotic therapy. The duration of follow-
up was short in both studies (9 to 11 weeks [26] and
10 days [27]).
Quality
A risk-of-bias study is outlined in Additional file 4. The
randomization process was not described clearly in ei-
ther of the included studies. The nature of blinding of
the investigator or subject to the intervention received
was not clearly stated in either study. Outcome mea-
sures were not clearly defined and were often subjective.
The basis of some statistical calculations in both trials
was not reported, with only a P value provided. No add-
itional information on study methodology, results or
analysis was received following approaches to the study
investigators.
Outcomes
The chosen outcome measures were different in each
study. Bassil et al. [26] performed a repeat laparoscopy
at 9 to 11 weeks after the start of treatment and evalu-
ated residual inflammation on inspection, peritoneal cy-
tology, histological study of adhesions and tubal patency
(categorized as mild, moderate or severe). These findings
formed the basis of a subjective prognosis regarding fer-
tility for each woman. In contrast, the primary outcome
reported by Goffi et al. [27] was subjective resolution of
adnexal pain on bimanual examination, or suprapubic
and iliac fossa pain on palpation.
The key findings from the included studies are summa-
rized in Table 1. A meta-analysis was not performed,
owing to the heterogeneity and low methodological qual-
ity of the identified studies.
Discussion
Effectiveness of NSAIDs
The studies included in this review provide insufficient
data to support the use of NSAIDs in the prevention of
long-term complications of PID. The use of NSAIDs was
Table 1 Summary of included studies
Study
design




40 Co-amoxiclav 1 g three times daily
doxycycline 200 mg once daily
intravenously for 5 days followed by
co-amoxiclav 500 mg three times
daily for 15 days and doxycycline










Tubal patency: in severe PID,
bilateral patency was seen in 1/7
(14.2%) of placebo group versus 7/9
(77.8%) of intervention group




Residual adhesions: in severe PID,
more patients in intervention group
had no residual adhesions, 6/9
(66.7%), versus control group, 1/7
(14.3%) (P = 0.06, Fisher’s exact test)
No difference between arms in tubal
patency or residual adhesions for
mild or moderate PID
[27] RCT Mild acute
PID




daily for 7 days
Intention
to treat
Suprapubic pain: resolution of pain
occurred by day 7 in 9/21 (43%) of
patients in the intervention group
versus 5/21 (24%) in the control
group (P = 0.2, χ square)
Clinical
diagnosis
Reduction in overall signs and
symptoms: greater reduction in
average score for severity of signs
and symptoms in the intervention
compared with the placebo group
(figures providing the basis of the
calculation not provided)
Nausea reported in 4/21 patients
receiving fentiazac (1 discontinuation)
versus 2/21 in the control group (no
discontinuations)
NSAID nonsteroidal anti-inflammatory drug; PID pelvic inflammatory disease; RCT randomized controlled trial.
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pain and overall symptoms but the studies had limited
power and were of low quality.
A role for NSAIDs in the reduction of inflammation
and prevention of adhesions, through COX-2 inhibition,
has been demonstrated in animal models but there is no
comparable data for their effectiveness in altering the clin-
ical course of inflammatory conditions in human subjects.
For example, there is no evidence to suggest that NSAIDs
modify the course of rheumatoid arthritis, where their ef-
fect is limited to symptomatic benefit [28]. Furthermore,
the regular use of NSAIDs has to be balanced against their
significant adverse effects including gastrointestinal haem-
orrhage, renal impairment and interactions with other
commonly prescribed medication.
Inflammation appears to be central to the development
of complications associated with PID and therefore other
agents that modulate the immune system, including corti-
costeroids and biological immune modulators, might have
a role in their prevention. Sanfilippo [29], in a case control
study that involved incision and eversion of rat proximal
uterine horns, treated the animals pre- and postoperatively
with either corticosteroid or normal saline injections. Beta-
methasone phosphate produced a significant reduction infibrosis when compared with all other corticosteroids or
control solutions.
Quality of included studies
A small number of individuals were included, with a total
of only 82 patients identified from two studies. The marked
differences between trials in antibiotic regimen used, treat-
ment intervention and outcome measures meant that it
was inappropriate to pool data for analysis. Both studies
were described as RCTs but neither described their method
of generating a random allocation sequence, their method
of allocation concealment or who was blinded to the allo-
cation schedule. A single operator was used to perform the
second-look laparoscopies in the Bassil study [26] in an at-
tempt to reduce inter-observer variability in reporting. It is
not stated, however, whether the operator was blinded to
the intervention received. In the Goffi study [27], there was
no description of the placebo drug and how it compared in
appearance and method of administration to fentiazac. The
pain assessment was not validated and, in view of the sub-
jective nature of pain and its reporting, inadequate blinding
may have introduced bias.
The antibiotic therapy regimen given to women varied
considerably between studies and was suboptimal when
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and American guidelines recommend the use of broad-
spectrum antibiotics to cover Neisseria gonorrhoeae, Chla-
mydia trachomatis, and aerobic and anaerobic bacteria
commonly isolated from the upper genital tract. It is
therefore unclear to what extent a suboptimal antibiotic
regimen might have contributed to the reported clinical
outcomes, including the persistence of pain and inflam-
mation, although if randomization was robust then this
should not have introduced systematic bias. The poten-
tial for bias is summarized in Additional file 4.
Patients included in the Bassil study [26] underwent an
initial laparoscopy during which their presenting diagnosis
was confirmed. This initial procedure enabled adhesioly-
sis, drainage of abscesses and peritoneal cavity lavage to
be performed. Bessil et al. [26] concluded that a signifi-
cantly greater number of those with severe PID treated
with NSAIDs had fewer residual adhesions and a higher
rate of tubal patency at second-look laparoscopy. Whilst
the interventions performed during the initial laparoscopy
were undertaken in both intervention and control groups,
this would not be routinely performed in clinical practice
and may limit the generalizability of the results.
Goffi et al. [27] reported a significant reduction in supra-
pubic pain in the group receiving a NSAIDs, compared
with the control group. However, the basis of the statistical
calculation was not clear from the data presented.Strengths and weaknesses
This is the first systematic review of the effectiveness of
NSAIDs in the treatment of PID. A comprehensive litera-
ture review including grey literature and unrestricted by
language was performed but it remains possible that rele-
vant studies were missed. All relevant identified articles
were obtained. The review complied with and is reported
according to PRISMA guidelines (Additional file 5). English
translations were obtained for foreign language papers,
including both studies included in the analysis, and a
number of studies were excluded based on translations
of abstracts.Conclusions
There is insufficient data to support a recommendation
for routine use of NSAIDs in the management of PID
to reduce inflammatory complications. Further RCTs
incorporating currently recommended antibiotic regimens
with objective short and long-term outcome measures are
needed to inform any change in clinical practice.Key findings
Inflammation is considered central to the development
of acute and chronic reproductive complications of PID.NSAIDs are used in the management of PID. Animal
studies indicate that NSAIDs may reduce inflammation
and fibrosis.
There is insufficient data to support or refute the efficacy
of NSAIDs in preventing the complications of PID.
Additional files
Additional file 1: Search strategy.
Additional file 2: Grey literature search.
Additional file 3: Data extraction form.
Additional file 4: Risk-of-bias summary.
Additional file 5: PRISMA checklist.
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